Looking to highlight a funding opportunity? Please send a brief description, link, and deadline to email@example.com
State & Federal Programs
The National Cancer Institute (NCI) announces the availability of a funding opportunity aimed at accelerating the development and commercialization of highly innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. This Program Announcement complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating a path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches. Click here to learn more.
Receipt Dates: May 28, 2014; November 4, 2014; May 27, 2015; November 4, 2015; May 27, 2016
Deadline: October 3, 2014, 12:00 pm, US Central Time
In 2015, the Falk Medical Research Trust will launch a new Transformational Research Program focused on increasing the impact of its funding. Since the Transformational Research Program utilizes an innovative approach that represents a departure from the Trust’s previous programs, the Catalyst Research Program has been created to provide seed funding to help investigators and their institutions lay the foundation for successful application to the Transformational Research Program in 2015 and beyond.
Successful research proposals to both programs must demonstrate direct relevance to human disease and the ability to extend basic research in one or more of the following ways:
- Understanding underlying disease processes and how they disrupt normal human biology,
- Identification of biological markers of disease activity and progression
- Development and testing of diagnostic or prognostic tests based on those markers
- Identification of targets for therapeutic interventions
- Development of therapeutic agents that will disrupt, arrest, or prevent the disease process
- Pre-clinical and clinical testing of new therapies
Award Amount and Funding Period:
- 1-year Projects of up to $500,000
- Up to $6 Million will be awarded in 2014
- Funding begins on or by November 30, 2014
Deadline: September 29
The HBS-HMS Health Acceleration Challenge is open to all (no Harvard affiliation necessary) and looking for proven ideas that have the potential to do great things for the U.S. health care delivery system. Innovations must have credible, demonstrated evidence of their value proposition (such as cost savings, outcomes improvement, patient satisfaction, etc.); have a compelling dissemination plan; and be at the cusp of scaling. Finalists will get a case written about them, share $150,000, and have the opportunity to present at the Forum on Health Care Innovation conference in April.
Deadline: No deadline; applications accepted anytime
One-year grants to jump start new ideas in PD research. The Rapid Response Innovation Awards (RRIA) program supports high-risk, high-reward projects with little-to-no existing preliminary data, but with potential to significantly impact our understanding of Parkinson’s disease. Moreover, this program is well-suited for early exploratory studies that may open the field up to new targets or pathways that may ultimately feed the early drug development pipeline for a treatment of PD.
There is no deadline to apply; submit an Expressions of Interest here.
DELSIA is an independent nonprofit venture philanthropy affiliate of the autism research and advocacy foundation Autism Speaks. DELSIA provides funds to for-profit partners to advance the development of products that address unmet medical and behavioral health needs of the autism community. It was created as an innovative funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by ensuring that scientific breakthroughs and technological advances are developed into products that improve health and quality of life for individuals with autism and their families. Our purpose is to transform lives by serving as a catalyst to facilitate and accelerate the delivery and availability of impactful products.
OneStart: Your chance to win US$150k to realise your biotech business idea
Deadline: December 1st, 2014.
Do you have an idea to solve a critical problem healthcare? Or do you have the scientific or business know-how to help someone else develop their idea?
The Oxbridge Biotech Roundtable (OBR) and SR One, the venture capital arm of GlaxoSmithKline, have teamed up again for the OneStart competition - the largest biotech startup accelerator programme in the world - to offer young innovators from all disciplines the chance to win US$150k with free lab space and ongoing legal and business advice from our sponsors to transform their ideas into a successful business.
Ideas at all stages of development are welcome. All semi-finalists will be directly mentored by experienced industry professionals for at least six weeks, and invited to attend a biotech business bootcamp in San Francisco in February 2015 with workshops from our global partners, including SR One, Johnson & Johnson Innovation, Takeda Ventures, Roche, McKinsey, and others.
To learn more about the programme and start building your team, visit www.oxbridgebiotech.com/onestart.
If you have any questions at all, please do get in touch via firstname.lastname@example.org. We would be happy to answer your questions about OneStart and help you move science forward to benefit human health.